GlaxoSmithKline Pharmaceuticals announced Q2FY24 & H1FY24 results:
- Revenue from operations: Rs 953 crore, with a 5% YoY growth.
- PBT: Rs 297 crore, showing a solid 13% YoY increase.
- EBITDA margins: 30.1%.
- Revenue from operations: Rs 1,691 crore, recording a 3% YoY growth.
- PBT: Rs 458 crore, improved by 9% YoY.
- EBITDA margins: 25.3%.
Commenting on the results, Bhushan Akshikar, Managing Director, GlaxoSmithKline Pharmaceuticals, said, "Our Q2 performance reflects an overall recovery with market share gains in several key promoted brands across all business units. We held leadership positions for our key brands in relevant therapy areas such as anti-infectives and dermatology.
Our focus in the coming quarters will remain on strong volume-led performance in General Medicines and Pediatric vaccines. We will also explore innovative solutions using Omnichannel strategy to expand our reach and coverage to our target segments. We continue to drive the expansion of the adult immunisation category with Shingrix (Zoster Vaccine Recombinant, Adjuvanted).”